Fintel reports that on December 12, 2023, Deutsche Bank initiated coverage of Amylyx Pharmaceuticals (BATS:AMLX) with a Buy recommendation.
Analyst Price Forecast Suggests 182.02% Upside
As of November 27, 2023, the average one-year price target for Amylyx Pharmaceuticals is 40.19. The forecasts range from a low of 27.27 to a high of $48.30. The average price target represents an increase of 182.02% from its latest reported closing price of 14.25.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Amylyx Pharmaceuticals is 178MM, a decrease of 39.51%. The projected annual non-GAAP EPS is -2.35.
What is the Fund Sentiment?
There are 171 funds or institutions reporting positions in Amylyx Pharmaceuticals. This is an increase of 5 owner(s) or 3.01% in the last quarter. Average portfolio weight of all funds dedicated to AMLX is 0.19%, a decrease of 1.78%. Total shares owned by institutions increased in the last three months by 9.36% to 15,744K shares. 
The put/call ratio of AMLX is 0.88, indicating a bullish outlook.
What are Other Shareholders Doing?
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,659K shares representing 2.46% ownership of the company. No change in the last quarter.
NAESX - Vanguard Small-Cap Index Fund Investor Shares holds 1,385K shares representing 2.05% ownership of the company. In it's prior filing, the firm reported owning 1,387K shares, representing a decrease of 0.21%. The firm decreased its portfolio allocation in AMLX by 11.19% over the last quarter.
IWM - iShares Russell 2000 ETF holds 1,183K shares representing 1.75% ownership of the company. In it's prior filing, the firm reported owning 1,158K shares, representing an increase of 2.09%. The firm decreased its portfolio allocation in AMLX by 9.30% over the last quarter.
ETAHX - Eventide Healthcare & Life Sciences Fund Shares holds 1,117K shares representing 1.65% ownership of the company. No change in the last quarter.
VISGX - Vanguard Small-Cap Growth Index Fund Investor Shares holds 775K shares representing 1.15% ownership of the company. In it's prior filing, the firm reported owning 795K shares, representing a decrease of 2.47%. The firm decreased its portfolio allocation in AMLX by 11.35% over the last quarter.
Amylyx Pharmaceuticals Background Information
(This description is provided by the company.)
Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
